research Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
Chemotherapy often causes skin and hair issues, but early management can help improve patient care.
Search
for
Sort by
Research
120-150 / 1000+ resultsresearch Treatment of acne with intermittent isotretinoin, cohort study
Intermittent isotretinoin can cause various skin, hair, and nail changes.
research EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
research PRIDE Complex (Papulopustules and/or Paronychia, Regulatory Abnormalities of Hair Growth, Itching, Dryness Due to EGFR Inhibitors)
PRIDE complex side effects from EGFR inhibitors can be managed without stopping treatment.
research Erosive pustular dermatosis of the scalp due to EGFR inhibitors: A multicentric study by EADV task force of ‘Dermatology for Cancer Patients’
Erosive pustular dermatosis of the scalp can occur about 17 weeks after starting EGFR inhibitors, and early minocycline may help manage it.
research A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib
Erlotinib can cause nonscarring hair loss and itchy skin.
research A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor
New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.
research Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies
Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
research Continuous MEK inhibition by AZD6244 (ARRY-142886) results in exhaustion of the cutaneous keratinocytic stem cell pool and resembles senescence driven skin aging
AZD6244 treatment causes skin aging effects by depleting skin stem cells.
research Advances in the Management of Cutaneous Toxicities of Targeted Therapies
Targeted cancer therapies often cause skin problems that need careful management to improve patient quality of life and treatment success.
research A linear and reticulate crusted keratotic papulopustular eruption: a rare presentation of PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) complex
A rare skin reaction from cancer treatment was successfully managed with topical treatments and antihistamines.
research Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
research Rash from EGFR inhibitors: Opportunities and challenges for palliation
EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.
research Topical Inhibition of the Electron Transport Chain Can Stimulate the Hair Cycle
Applying certain inhibitors to the skin can promote hair growth without harming cells.
research Erosive pustular dermatosis of the scalp following topical ingenol mebutate for actinic keratoses
Two elderly men developed scalp inflammation after using a gel for skin lesions, which healed with treatment except for some permanent hair loss.
research Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
Skin problems like acne, dry skin, and nail and hair changes are common in patients taking EGFR inhibitors.
research EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.
research Folliculitis Decalvans-like Alopecia During Treatment With EGFR Inhibitors for Lung Cancer: A Case Series of 6 Patients
Some lung cancer patients treated with EGFR inhibitors may develop a hair loss condition similar to folliculitis decalvans.
research Síndrome PRIDE: una práctica forma de identificar los efectos adversos cutáneos de los inhibidores del EGFR
PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
research Chemotherapy and Cutaneous Drug Reactions
Chemotherapy can cause skin side effects that affect patients' lives, but they can be managed to avoid interrupting cancer treatment.
research Trichomegaly of the eyelashes following treatment with cetuximab
Cetuximab can cause excessive eyelash growth.
research Bacteria induce skin regeneration via IL-1β signaling
Skin bacteria, specifically Staphylococcus aureus, help in wound healing and hair growth by using IL-1β signaling. Using antibiotics on skin wounds can slow down this natural healing process.
research Drug-induced acne
Some medications can cause acne, and stopping these drugs is the main treatment.
research IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.
research Neutralization of IL-8 Prevents the Induction of Dermatologic Adverse Events Associated with the Inhibition of Epidermal Growth Factor Receptor
Blocking IL-8 can reduce skin rashes from cancer treatment.
research A Case of Cicatricial Alopecia Associated with Erlotinib
Erlotinib can cause hair loss as a side effect.
research Role for the Epidermal Growth Factor Receptor in Chemotherapy-Induced Alopecia
Targeting EGFR may help reduce hair loss from chemotherapy.
research Skin toxicity caused by EGFR antagonists—An autoinflammatory condition triggered by deregulated IL‐1 signaling?
Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.
research Patients with bullous skin disease in a high‐epidemic COVID‐19 area, Bergamo, Italy
Oral mTOR inhibitors often cause skin and hair side effects but usually don't require stopping treatment.
research Perifollicular Xanthomas Associated with Epidermal Growth Factor Receptor Inhibitor Therapy
EGFR inhibitors can cause yellowish skin eruptions.